- Conditions
- Prostate Cancer
- Interventions
- Neoadjuvant Hormonal Therapy, Docetaxel
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1489–1512
of 1,889
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Interventions
- stereotactic radiosurgery, magnetic resonance imaging, quality-of-life assessment, Serum Prostate Antigen Test, Digital Rectal Exam, Expanded Prostate Cancer Index Composite
- Radiation · Device · Other + 2 more
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Prostate Cancer, Prostatic Neoplasms
- Interventions
- Cabazitaxel plus bavituximab
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Adenocarcinoma, Prostate Cancer
- Interventions
- Stereotactic Body Radiation Therapy
- Radiation
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 1
- States / cities
- Lake Success, New York
- Conditions
- Recurrent Prostate Carcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
- Interventions
- Bicalutamide, Goserelin Acetate, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine, Recombinant Vaccinia-TRICOM Vaccine, Sargramostim
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 7
- States / cities
- Jacksonville, Florida • Chicago, Illinois • Indianapolis, Indiana + 3 more
- Conditions
- Prostate Cancer
- Interventions
- behavioral dietary intervention, dietary intervention, therapeutic dietary intervention
- Behavioral · Dietary Supplement · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Castration-Resistant Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Decitabine and Cedazuridine, Enzalutamide
- Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Genetic testing, Valemetostat Tosylate, Magnetic Resonance Imaging, Computed Tomography, Bone scan, FDG-Positron Emission Tomography, PSMA PET Scan, Biospecimen Collection, Carboplatin, Cabazitaxel, Abiraterone Acetate, Enzalutamide, Lutetium Lu 177 Vipivotide Tetraxetan
- Other · Drug · Procedure
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 474 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Chico, California + 91 more
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel (Taxotere)
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Adenocarcinoma of the Prostate
- Interventions
- Muscadine Plus, Placebos
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 13
- States / cities
- Duarte, California • La Jolla, California • Aurora, Colorado + 10 more
- Conditions
- Prostate Cancer
- Interventions
- SipT Treatment, Ipilimumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 2
- States / cities
- San Francisco, California • Houston, Texas
- Conditions
- Prostate Specific Antigens, Prostate Neoplasms
- Interventions
- T-cell receptor alternate reading frame protein (TARP) peptide vaccine, T-cell receptor alternate reading frame protein (TARP) dendritic cell vaccine
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostatic Neoplasm
- Interventions
- AAA617, AAA517, Piflufolastat F 18, ARPI, ADT, Best supportive care
- Drug · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Athens, Georgia • Indianapolis, Indiana + 7 more
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Sunitinib, EBXRT
- Drug · Radiation
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • New Brunswick, New Jersey • Durham, North Carolina
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Acapatamab, Enzalutamide, Abiraterone, AMG 404
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Orange, California • San Francisco, California + 4 more
- Conditions
- Prostate Cancer
- Interventions
- Ultra-hypofractionated radiation therapy, Moderately Hypo-fractionated Radiation Therapy
- Radiation
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Cancer
- Interventions
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer
- Interventions
- pegylated liposomal doxorubicin hydrochloride, hyperthermia treatment
- Drug · Procedure
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 40 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 2
- States / cities
- Shreveport, Louisiana • Myrtle Beach, South Carolina
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Cancer (Diagnosis), Prostate Cancer Metastatic Disease
- Interventions
- PSMA PET/CT scan
- Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Bladder Outlet Obstruction, BPH
- Interventions
- High Intensity Focused Ultrasound
- Device
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 45 Years to 80 Years · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- calcitriol, dexamethasone
- Dietary Supplement · Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- MEDI-522, Docetaxel + Prednisone* + Zoledronic Acid
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 36
- States / cities
- Hoover, Alabama • Springdale, Arizona • Tucson, Arizona + 33 more
- Conditions
- Cancer, Fatigue
- Interventions
- Not listed
- Lead sponsor
- National Institute of Nursing Research (NINR)
- NIH
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pelvic Neoplasms
- Interventions
- HALO90 Ablation catheter
- Device
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio